<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30383624</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1536-5964</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>97</Volume>                    <Issue>44</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                    </PubDate>                </JournalIssue>                <Title>Medicine</Title>                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>            </Journal>            <ArticleTitle>Evaluation of the efficacy and safety of elemene in treating malignant pleural effusion caused by tumors: A PRISMA guided meta-analysis.</ArticleTitle>            <Pagination>                <MedlinePgn>e12542</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000012542</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Elemene is widely used to treat malignant pleural effusion in China. This meta-analysis aimed to evaluate the efficacy and safety of elemene in treating malignant pleural effusion.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Electronic databases including Pubmed, the Cochrane Library, Embase and Chinese biomedical literature database were searched until March 2017. Clinical controlled trials (CCTs) assessing the efficacy and safety of elemene in the treatment of malignant pleural effusion were included. The quality of the included studies was evaluated using the quality evaluation criteria of the Cochrane Handbook version 5.1.0.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 46 CCTs were included, with 2992 patients. Results of meta-analysis showed that elemene significantly improved the overall response rate (ORR) in controlling malignant pleural effusion (risk ratio [RR] = 1.16; 95% CI: 1.08-1.23; P &lt; .05). Subgroup results showed that the ORR of elemene in the treatment of lung cancer patients with malignant pleural effusion (RR = 1.20, 95% CI: 1.07-1.34; P &lt; .05) was higher than that of other cancers (RR = 1.14, 95% CI: 1.05-1.23; P &lt; .05). Meanwhile, elemene did not significantly increase the incidences of chest pain and fever (P &gt; .05).</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Elemene is suggested to have the ability of improving the treatment outcome of malignant pleural effusion with acceptable safety.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Qing-Tao</ForeName>                    <Initials>QT</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Cardiothoracic and Breast Surgery, Xiang Yang No. 1 People's Hospital, HuBei University of Medicine, XiangYang, Hubei, P.R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Ze-Lin</ForeName>                    <Initials>ZL</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Xiong</LastName>                    <ForeName>Hui</ForeName>                    <Initials>H</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Zhou</LastName>                    <ForeName>Dong-Sheng</ForeName>                    <Initials>DS</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Jun</ForeName>                    <Initials>J</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Liang</LastName>                    <ForeName>Jian</ForeName>                    <Initials>J</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Ya-Fei</ForeName>                    <Initials>YF</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D017418">Meta-Analysis</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Medicine (Baltimore)</MedlineTA>            <NlmUniqueID>2985248R</NlmUniqueID>            <ISSNLinking>0025-7974</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D012717">Sesquiterpenes</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>11029-06-4</RegistryNumber>                <NameOfSubstance UI="C038905">elemene</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>AIM</CitationSubset>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016066" MajorTopicYN="N">Pleural Effusion, Malignant</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012717" MajorTopicYN="N">Sesquiterpenes</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>2</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>2</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30383624</ArticleId>            <ArticleId IdType="doi">10.1097/MD.0000000000012542</ArticleId>            <ArticleId IdType="pii">00005792-201811020-00002</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>